PRQRNasdaq

ProQR Therapeutics N.V.

Healthcare·Healthcare·Leiden, Netherlands

ProQR Therapeutics N.V. (PRQR): ~21 mo cash runway. Updated within the last hour.

7.0/10

BioSniper Score

2-factor signal · derived from public data

Cash Runway5.9

21.3 months

Financial Health8.1

D/E 1.28 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline BreadthN/A

N/A

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ProQR Therapeutics N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$176.0M

Cash

$92.4M

Quarterly Burn

$13.4M

Runway

21.3 mo

Revenue

$4.7M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2028
Today~23 mo out
Catalyst within runway

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

64

Total value held

$35.3M

HolderSharesValue
adage capital partners gp, l.l.c.6,253,467$10.1M
affinity asset advisors, llc2,454,278$4.0M
dafna capital management llc1,567,561$2.5M
morgan stanley1,299,775$2.1M
platinum investment management ltd1,235,514$2.0M
walleye capital llc1,215,058$2.0M
two sigma investments, lp918,857$1.5M
point72 asset management, l.p.755,842$1.2M
citadel advisors llc703,323$1.1M
nomura asset management international inc.620,000$1.0M

Showing top 10 of 64 institutional holders of ProQR Therapeutics N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Daniel Anton de Boer

Frequently asked questions

What is ProQR Therapeutics N.V.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ProQR Therapeutics N.V. has approximately 21.3 months of cash runway.

What is ProQR Therapeutics N.V.'s market capitalization?

ProQR Therapeutics N.V.'s market capitalization is approximately $176.0M.

Who is the CEO of ProQR Therapeutics N.V.?

Mr. Daniel Anton de Boer is the chief executive officer of ProQR Therapeutics N.V. (PRQR).

Get the full picture on ProQR Therapeutics N.V.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.